Issue #10 June 2021
atcormedical.com • 2 minute read
Welcome to VITALITY.
You’re receiving this newsletter because you’re a customer, partner, or you’ve otherwise subscribed or opted in at one of our events, conferences, or website.
As the summer continues to heat up, we are excited to share new partnerships, new patent applications and new research projects. Last week we announced a new partnership in innovation with LifeQ to power the CONNEQT Band — a disruptive and innovative new health wearable. CardieX also announced new health sensor patent applications to cover gaming, computer devices, and other electronic hardware.
CardieX subsidiary, ATCOR’s SphygmoCor® XCEL System was also recently selected to for an important clinical trial at Yale University focused on maternal health.
Stay healthy, stay strong,
CardieX’s consumer brand CONNEQT, announced a Collaborative Agreement to leverage each company’s IP for the CONNEQT Band, expected to be the world’s first AI-powered, FDA cleared, clinical grade smart health band with dual-PPG sensing tech.
Hypertension during pregnancy is a cause of maternal morbidity in 6.5% of women, but is preventable. To better understand and prevent this dangerous condition, Yale University’s ASPPIRE trial is using ATCOR’s SphygmoCor® XCEL System to measure central blood pressure in its study of aspirin to prevent pre-eclampsia. For more, click here
CardieX subsidiary ATCOR expanded its patent application to cover a system and method for obtaining those same heart and arterial health indicators from PPG sensors in a multitude of electronic devices including laptops and computer ID sensors, mouse devices, computer gaming controls, and keyboards. The company currently holds more than 14 patents in blood pressure and wearable sensor technologies which are being built into new CONNEQT devices.
We’d love to hear from you
You can unsubscribe at any timeSubscribe